Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

NCT06838832 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-hodgkin Lymphoma,B Cell

Interventions

BIOLOGICAL: Allogenic CD19-CAR-γδT cell
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Chinese PLA General Hospital